P. Fargeot

发表

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Polyadenylic–Polyuridylic Acid Plus Locoregional Radiotherapy Versus Chemotherapy with CMF in Operable Breast Cancer: a 14 Year Follow-up Analysis of a Randomized Trial of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)

T. Delozier, A. Laplanche, P. Fargeot, 2000, Breast Cancer Research and Treatment.

Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer

S. Lizard-Nacol, P. Fargeot, P. Colosetti, 1999, Breast Cancer Research.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1996, European journal of cancer.

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

W. Brugger, G. Romieu, P. Fargeot, 2007, Critical reviews in oncology/hematology.

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

J. Bonneterre, M. Campone, S. Urien, 2003, Cancer Chemotherapy and Pharmacology.

Sensitivity and specificity of thallium-201 scintigraphy for the diagnosis of malignant vertebral fractures.

J. Thariat, F. Brunotte, P. Fargeot, 2004, European journal of radiology.

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

P. Fumoleau, C. Hill, P. Fargeot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Sclerosing epithelioid fibrosarcoma: a fibrosarcoma with a very long course].

F. Collin, P. Fargeot, L. Arnould, 2000, Annales de pathologie.

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

T. Delozier, D. Spaeth, P. Biron, 2008, Bone Marrow Transplantation.

Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer

S. Lizard-Nacol, P. Fargeot, N. Franco, 2000, Breast Cancer Research and Treatment.

Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.

J. Bonneterre, L. Mauriac, M. Tubiana, 1985, European journal of cancer & clinical oncology.

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer

M. Piccart, A. Bottomley, T. Čufer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis

B. Chauffert, P. Fumoleau, P. Fargeot, 2006, Anti-cancer drugs.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

S. Culine, G. Deplanque, J. Droz, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients].

P. Fargeot, C. Lhommé, A. Goupil, 1993, Bulletin du cancer.

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

T. Delozier, M. Namer, L. Mauriac, 2005, Breast Cancer Research and Treatment.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.

J. Droz, M. Spielmann, P. Fargeot, 1991, European journal of cancer.

Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial.

P. Biron, J. Droz, P. Fargeot, 1993, European urology.

Phase III Trial of Early Intensified Chemotherapy (HDCT) with Autologous Bone Marrow Transplantation (ABMT) in First Line Treatment of Poor Risk Non-Seminomatous Germ Cell Tumours (NSGCT): Long Term Results of a Randomised Trial

P. Biron, J. Droz, P. Fargeot, 1994 .

Radiation Therapy and Tamoxifen: Concurrent or Sequential? It's No Longer the Question!

P. Fargeot, 2012 .

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.

J. Bonneterre, M. Tubiana-Hulin, M. Spielmann, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.

S. Lizard-Nacol, P. Fargeot, P. Genne, 1999, Anticancer research.

CD 15 antigen in Hodgkin's disease.

F. Collin, T. Petrella, P. Fargeot, 1989, Pathology, research and practice.

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.

B. Bui, P. Fargeot, D. Cupissol, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.

M. Namer, J. Bonneterre, M. Campone, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

J. Bergh, M. Piccart, R. Coombes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

S. Schraub, M. Namer, J. Bonneterre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.

L. Collette, D. Lacombe, W. Fiedler, 2006, European journal of cancer.

Phase II Trial of Cystemustine, a New Nitrosourea, as Treatment of High-grade Brain Tumors in Adults

J. Madelmont, P. Fumoleau, P. Fargeot, 2000, Journal of Neuro-Oncology.

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

Impact of UFT on tumoral TS and DPD levels in colorectal cancer.

G. Milano, P. Fargeot, P. Formento, 2000, Oncology.

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.

S. Schraub, M. Namer, J. Bonneterre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10-year follow-up update of French adjuvant study group 05 trial: FEC 100 regimen remains superior to FEC 50 in adjuvant chemotherapy of poor prognosis, node-positive, early breast cancer patients

M. Namer, J. Bonneterre, P. Fumoleau, 2003 .

No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

P. Biron, J. Droz, P. Fargeot, 1994 .

Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.

J. Bonneterre, L. Mauriac, P. Fargeot, 1988, European journal of cancer & clinical oncology.

Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha-fetoprotein-producing lung tumor.

F. Collin, T. Petrella, P. Fargeot, 1997, The American journal of surgical pathology.

An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.

M. van Glabbeke, H. Earl, J. Armand, 1984, European journal of cancer & clinical oncology.

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

J. Bonneterre, M. Campone, S. Urien, 2004, Cancer Chemotherapy and Pharmacology.

Phase II clinical evaluation of doxifluridine.

S. Schraub, J. Armand, P. Fumoleau, 1986, Cancer treatment reports.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer ( mCRPC ) with or without neuroendocrine differentiation : results of the French GenitoUrinary Tumor Group ( GETUG ) P 01 trial

S. Culine, G. Deplanque, J. Droz, 2011 .

Efficacy of lenograstim on hematological tolerance to maid chemotherapy in sarcoma patients and impact on dose intensity

P. Fargeot, D. Cupissol, F. Bonichon, 1993 .

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

J. Bonneterre, A. Monnier, P. Fumoleau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer

A. Ravaud, G. Deplanque, J. Bay, 2008, Clinical Cancer Research.

Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin

T. Conroy, G. Prévot, M. Spielmann, 1994, American journal of clinical oncology.

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

M. Piccart, A. Bottomley, T. Čufer, 2004, European journal of cancer.

[Germ cell testicular tumors. Three therapeutic periods].

P. Fargeot, 1990, Bulletin du cancer.

Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.

B. Chauffert, P. Fargeot, N. Isambert, 2001, Journal of experimental & clinical cancer research : CR.

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2009, Investigational New Drugs.

Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.

J. Bonneterre, P. Fargeot, P. Kerbrat, 1991, European journal of cancer.

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

S. Schraub, M. Namer, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].

P. Fargeot, J. Berlie, M. George, 1990, Bulletin du cancer.

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).

B. Esterni, F. Joly, F. Retornaz, 2010, Critical reviews in oncology/hematology.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

M. Piccart, L. Duchateau, C. Lohrisch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UFT/leucovorin plus vinorelbine combination for advanced breast cancer.

J. Bonneterre, P. Fumoleau, P. Fargeot, 2000, Oncology.

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

M. Namer, J. Bonneterre, A. Monnier, 2002, British Journal of Cancer.

Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.

S. Leyvraz, P. Fargeot, T. Facchini, 1993, Cancer investigation.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].

I. Barillot, P. Fargeot, J. Riedinger, 1997, Bulletin du cancer.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation

S. Culine, P. Biron, J. Droz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in long-term survivors of nonseminomatous germ cell testicular tumors.

J. Droz, P. Fargeot, Y. Allain, 1993, The Journal of urology.

Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.

M. Namer, P. Fargeot, G. Blackledge, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.

J. Droz, P. Fargeot, G. Piot, 1987, Progress in clinical and biological research.

Implication of the Epstein-Barr virus in the progression of chronic lymphocytic leukaemia/small lymphocytic lymphoma to Hodgkin-like lymphomas.

F. Collin, T. Petrella, P. Fargeot, 1997, Anticancer research.

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

P. Fargeot, D. Cupissol, S. Brienza, 1996, European journal of cancer. Part B, Oral oncology.

p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer.

P. Fargeot, J. Riedinger, B. Coudert, 1997, International Journal of Oncology.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Premenopausal Patients with Node-Positive Resectable Breast Cancer

S. Schraub, M. Namer, P. Fumoleau, 2012, Drugs.

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients

W. Bezwoda, P. Fargeot, G. Falkson, 2000, Cancer Chemotherapy and Pharmacology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

[Randomized trial of initial chemotherapy with cisplatin alone or in combination in 241 advanced carcinomas of the upper respiratory and digestive tract].

P. Fargeot, L. Meeus, L. Traissac, 1988, Annales d'Oto-Laryngologie et de Chirurgie Cervico-Faciale.

[A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck. Analysis of a series of 209 patients].

P. Fargeot, L. Meeus, J. Chauvergne, 1988, Bulletin du Cancer.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.

M. van Glabbeke, P. Fumoleau, V. Diéras, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trials of Tetrahydropyranyl‐Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma

P. Hérait, J. Armand, P. Fumoleau, 1993, American journal of clinical oncology.

Phase II study of cystemustine in advanced eenal cancer

J. Madelmont, V. Diéras, P. Fargeot, 1995 .

The value of health-related quality of life assessment in cancer clinical trials

P. Fargeot, C. Coens, F. Efficace, 2007 .

Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial.

A. Ravaud, G. Deplanque, J. Bay, 2006, Journal of Clinical Oncology.